In the first stage, the production setup will enable an annual production capacity of $4M in revenues
The completion of the production setup is expected during the fourth quarter, 2023
(Yokneam Illit, July 5, 2023) NextFerm Technologies Ltd. (TASE:NXFR), a food-tech company developing ProteVin, a vegan, fermentation-based, non-GMO protein alternative and other innovative yeast-based nutrients, announced today that it has entered into a commercial manufacturing agreement with a subcontractor in India, Kothari Fermentation and Biochem, for the production of ProteVin. The agreement relates only for production services and doesnt include IP transfer to the subcontractor.
The company's management has worked diligently to find a solution to establish a production setup that will be in line with its financial means, so that, in this stage, this agreement replaces the establishment of the manufacturing plant with the subcontractor in North Macedonia, and will allow the company to supply market demands with a lower investment than planned and with the ability to increase future capacity. In the first stage, the production setup will enable an annual production capacity of $4M in revenues. In addition to the production equipment that the company has purchased so far, the Company estimates that the necessary investment needed for the completion of the production setup and the purchase of the production equipment for the first stage will be approximately $2M. This investment will be financed from the company's own resources.
The completion of the production setup is expected during the fourth quarter, 2023. The building in which the production facility is planned to be built already exists and has needed utilities, and most of the equipment needed to operate it has already been purchased by the company and/or is in the possession of the subcontractor and is available for the companys use.
Starting 2023, five food and dietary supplement companies in the USA and Europe have launched vegan products based on ProteVin, including Swanson, one of the leading and veteran nutritional supplement brands in the USA, Spacemilk and Mushroom Design. In the five products, the ProteVin brand is labeled on the packaging. The company has a wide and growing base of food and dietary supplement companies, including global companies, that are examining ProteVin for use in a variety of alternative products.
In addition to ProteVin, the production facility in India will allow the company to also produce and market the by-product Yeast Extract, which is obtained in the production process of the protein. This product is an ingredient that enhances taste and flavor in the food industry.
The company has developed a first generation of Yeast Extract based on a unique technology developed by the company (a yeast strain and unique processes) that contributes to the quality of the Yeast Extract products and the profitability of these products.
The Yeast Extract market is estimated at approximately $1.9 Billion in global annual sales, with a growth of approximately 8.7% which is influenced, among others, by the growth of the alternative food market. This is one of the most important and largest categories in the flavors market.
Boaz Noy, Chief Executive Officer of NextFerm, said: "In past few months, we have focused on finding an efficient and flexible production alternative to the production facility that was planned to be established in North Macedonia, which will be in line with the company's capabilities and financial resources.
The production setup that will be established in India will allow us to meet the growing demand for ProteVin, with a lower investment than planned with the ability to increase future capacity. ProteVin is the only alternative protein on the market today with a neutral taste and an animal-like nutritional value, and we believe it will become a leading solution in the global alternative protein industry. In addition, the company will be able to initiate the production and launch of Yeast Extract, which is a vegan food ingredient that enhances taste and flavor and with a high and growing demand in the food industry."
About Kothari Fermentation and Biochem
Kothari Fermentation and Biochem, traded on the Bombay Stock Exchange (BSE:KFBL.BO) is a manufacturer of bakers yeast, Instant Yeast, Active & Inactive Dried Yeast, Cell walls, yeast extract, alcohol yeast and other yeast based products.
For more information, visit the Kothari website at: www.kothariyeast.in
NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE:NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives.
NextFerm's flagship product is ProteVin, a vegan, yeast-derived protein with animal-like nutritional value (Amino acid profile BCAA=21%, Leucine=9%, EAA=53% and high digestibility PDCAAS=1) and a neutral flavor. ProteVin is designed for a variety of categories in the alternative protein market, which is estimated at USD 20 billion in terms of final products and at USD 3.5 billion in terms of raw materials with an annual growth rate of above 20%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. The Company launched ProteVin and initiated marketing and supplying the product in second quarter of 2022.
For more information, visit the NextFerm website at: www.nextferm.com
Legal Notice Regarding Forward-Looking Statements
This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Companys control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Companys operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Companys current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Companys operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors.
NextFerm Technologies Ltd.
Yossi Ohana – CFO
Investor and Media Contact
View source version on newsdirect.com: https://newsdirect.com/news/nextferm-technologies-announces-a-commercial-manufacturing-agreement-for-the-production-of-protevin-its-vegan-protein-with-kothari-fermentation-and-biochem-a-subcontractor-in-india-169410049
NextFerm Technologies Ltd.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Boston New Times journalist was involved in the writing and production of this article.